Markets:

Overview

News

Currencies

International

Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

33.38 +1.63 (+5.13%)

Streaming Delayed Price Updated: 12:08 PM EDT, Jun 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

3 Small-Cap Stocks with Questionable Fundamentals

June 11, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors. ↗

June 01, 2026

10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation.

Via The Motley Fool

Topics Regulatory Compliance

The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call

May 14, 2026

10x Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management c...

Via StockStory

Topics Artificial Intelligence Earnings

10x Genomics (NASDAQ:TXG) Beats Q1 Estimates But Falls as Revenue Shrinks Year-Over-Year ↗

May 07, 2026

Via Chartmill

United Natural Foods Stock Is Up 85%. One Investor Just Sold Out Completely ↗

May 12, 2026

United Natural Foods distributes natural, organic, and conventional groceries to a wide range of North American retailers.

Via The Motley Fool

Topics Economy Supply Chain

What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗

May 12, 2026

Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.

Via The Motley Fool

Topics Regulatory Compliance

This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% ↗

May 12, 2026

10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.

Via The Motley Fool

1 Cash-Producing Stock on Our Watchlist and 2 We Question

May 11, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

10x Genomics Q1 Earnings Call Highlights ↗

May 09, 2026

10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument...

Via MarketBeat

Topics Earnings

Why 10x Genomics (TXG) Stock Is Down Today

May 08, 2026

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expec...

Via StockStory

TXG Q1 Deep Dive: Atara Launch, Spatial Platform Transition, and AI-Driven Demand

May 08, 2026

Biotech company 10x Genomics (NASDAQ:TXG) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The com...

Via StockStory

10x Genomics (TXG) Q1 2026 Earnings Transcript ↗

May 07, 2026

10x Genomics (TXG) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Artificial Intelligence

10x Genomics’s (NASDAQ:TXG) Q1 CY2026: Beats On Revenue But Stock Drops

May 07, 2026

Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 mi...

Via StockStory

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

May 05, 2026

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after the bell. Here’s what to look for. 10x Genomics beat analys...

Via StockStory

1 Unprofitable Stock to Target This Week and 2 That Underwhelm

April 28, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Ignore

April 24, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Why 10x Genomics (TXG) Shares Are Trading Lower Today

April 23, 2026

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.4% in the afternoon session after a key industry peer, Thermo Fisher Scientific (TM...

Via StockStory

Topics Artificial Intelligence Government Stocks

3 Overrated Stocks We Keep Off Our Radar

April 17, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Topics Economy

3 Small-Cap Stocks We Steer Clear Of

April 09, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Economy Government Stocks

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 25, 2026

The widely followed investor has been buying stocks trading well below their all-time highs.

Via The Motley Fool

These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗

March 23, 2026

The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.

Via The Motley Fool

Topics Artificial Intelligence ETFs

3 Reasons to Sell TXG and 1 Stock to Buy Instead

March 20, 2026

10x Genomics has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 39.8% and now trades at $18.24. This...

Via StockStory

Topics Stocks Supply Chain

1 Cash-Producing Stock with Competitive Advantages and 2 We Ignore

March 16, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

3 Healthcare Stocks We’re Skeptical Of

March 13, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

3 Russell 2000 Stocks We Approach with Caution

March 10, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Topics Retirement

Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers

March 05, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its ...

Via StockStory

Topics Artificial Intelligence

The "Flight to Quality": Thermo Fisher’s Q4 Beat and Dividend Hike Cement Defensive Leadership for 2026

February 27, 2026

WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the...

Via MarketMinute

Topics Earnings Economy World Trade

3 Stocks Under $50 We’re Skeptical Of

February 26, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Topics Artificial Intelligence

5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

February 19, 2026

10x Genomics’ fourth quarter results saw stable revenue performance despite a subdued research funding environment, with management crediting continued consumables growth and increased adoption of new...

Via StockStory

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.